Tuesday, 25 Sep 2018

Drug Safety

Datesort ascending Type Title Save
16 Mar 2018 News Repeat Malignancy Unlikely with Biologic Therapy
15 Mar 2018 News Opportunistic Infections in RA Rare with Biologics
15 Mar 2018 Social Metanalysis of checkpoint inhibitor (nivolumab, pembrolizumab or atezolizumab)shows high rates of hypothyroidism (OR 7.6), pneumonitis (5.4), colitis (2.9), hypophysitis (3.4), rash (2.4), fatigue (32%), diarrhea (19%) &> 20% w/ arthraligia or back pain. https://t.co/1WMuRRCWZN
10 Mar 2018 Social The RheumNow Week in Review is Up! Listen to the podcast https://t.co/83DtTD8k9L or view the video there https://t.co/WpLP2XXFAw
08 Mar 2018 News Biologics in Pregnancy: Are They Safe?
08 Mar 2018 News DSB – Safety Updates & Drug Shortages – March 2018
07 Mar 2018 Social Checkout #RWCS fellow video by Dr. Anna Postolova as she presents a case of MTX in the Treatment of Granulomatosis Mastitis https://t.co/pt4wAPXsGr
05 Mar 2018 Social @RichardPAConway Read the article. While only a pilot study it showed that TCZ worked by all clinical parameters but that MRA looked poorly sensitive, even before Rx began. FDG-PET looks more reliable as an imaging assessment tool. https://t.co/r2r2oCk0Kj
05 Mar 2018 Social Rituximab associated adverse events are more common in treating lymphoma/leukemi ( 25-36%) than with autoimmune dz (9-17%) and are more common with splenomegaly, anemia, hx of allergies, age. https://t.co/gUREPFvbUb
02 Mar 2018 News Steroid Use During Rheumatoid Pregnancies
28 Feb 2018 News Inflammatory Arthritis Variants with Checkpoint Inhibitors
26 Feb 2018 Social Of 134 RTX treated pts (mean 79 mos), 23 (17%) developed Hypogammaglobulinemia after a mean 64 mos & assoc w/ 4x risk of severe infections. Gammaglobulin <8 g/L at baseline was a predictor of hypogamma (HR 7.34), but MTX was protective (HR 0.26) https://t.co/AMOtNAUeXR
26 Feb 2018 Social Nice update and review of Vaccination issues in Rheumatology - featuring insights from Drs. Len Calabrese, Steve Lindsey, Jeff Curtis, Kevin Winthrop & Betsy Kirchner ANP. https://t.co/xDTiO9xpHS
24 Feb 2018 Social Dr. Hyman Zimmerman is famous for drug-induced hepatocellular injury plus jaundice conferring a 10% mortality rate. "Hy's Law" is used by the FDA to judge serious hepatotoxicity and risk of death; Requires evidence of jaundice and ALT/AST >3x ULN https://t.co/fHa5ayHxmH
23 Feb 2018 Social Based on FDA review of a 10yr study, the FDA recommends that Biaxin (clarithromycin) not be used in patients with cardiac disesase as there may be a risk of increased risk of heart problems or death years later.
22 Feb 2018 News Equal Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS
21 Feb 2018 Social Dr. Hyman Zimmerman is famous for drug-induced hepatocellular injury plus jaundice conferring a 10% mortality rate. "Hy's Law" is used by the FDA to judge serious hepatotoxicity and risk of death; Requires evidence of jaundice and ALT/AST >3x ULN https://t.co/qu65fdGscf
21 Feb 2018 News ASCO/NCCN Guidelines for Checkpoint Inhibitor Immune-Related Adverse Events
16 Feb 2018 Social Pharmacovigilance using Twitter? A UK study compared glucocorticoid AE on Twitter vs UK MHRA regulatory system; in 3 yrs, Twitter Identified 20,210 Steroid AE, but only 3022 via MHRA. Twitter AE “common but not serious”, most being insomnia and weight gain https://t.co/T49kterWXS
15 Feb 2018 Social Lilly announces top line results of COAST-V trial showing the safety and efficacy of Taltz/ixekizumab (vs PBO vs adalimumab) in Ankylosing Spondylitis meeting primary and secondary endpoints (ASAS40) at 16 weeks. Resuts to likely be presented at EULAR https://t.co/0UBAjZTjDr